Claire Vilain
About
Claire Vilain is a scholar working on Neurology, Rehabilitation and Psychiatry and Mental health.
According to data from OpenAlex, Claire Vilain has authored 25 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Neurology, 13 papers in Rehabilitation and 8 papers in Psychiatry and Mental health. Recurrent topics in Claire Vilain's work include Botulinum Toxin and Related Neurological Disorders (19 papers), Stroke Rehabilitation and Recovery (13 papers) and Cerebral Palsy and Movement Disorders (8 papers). Claire Vilain is often cited by papers focused on Botulinum Toxin and Related Neurological Disorders (19 papers), Stroke Rehabilitation and Recovery (13 papers) and Cerebral Palsy and Movement Disorders (8 papers). Claire Vilain collaborates with scholars based in France, United States and Belgium. Claire Vilain's co-authors include Philippe Picaut, Allison Brashear, Jean‐Michel Graciès, Thierry Deltombe, Robert Jech, Marta Banach, Peter McAllister, Fatma Gül, Christina Marciniak and Peter Valkovič and has published in prestigious journals such as The Lancet Neurology, European Urology and Journal of the Neurological Sciences.
In The Last Decade
Claire Vilain
25 papers receiving 332 citations
Peers
Claire Vilain
Benjamin Zakine France
Serdar Koçer France
Maria Francesca Micello Italy
Angelika Hanschmann Germany
Emily Patrick Australia
Nicoletta Cinone Italy
Heather W. Walker United States
Svetlana Khatkova Russia
Susanne Grafe Germany
Paul Filipetti France
Citations per year, relative to Claire Vilain Claire Vilain (= 1×)
peers
Benjamin Zakine
Countries citing papers authored by Claire Vilain
Since
Specialization
Citations
This map shows the geographic impact of Claire Vilain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Vilain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Vilain more than expected).
Fields of papers citing papers by Claire Vilain
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Claire Vilain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Vilain. The network helps show where Claire Vilain may publish in the future.
Co-authorship network of co-authors of Claire Vilain
This figure shows the co-authorship network connecting the top 25 collaborators of Claire Vilain. A scholar is included among the top collaborators of Claire Vilain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Vilain. Claire Vilain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kennelly, Michael, Francisco Cruz, Sender Herschorn, et al.. (2022). Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2). European Urology. 82(2). 223–232.
2.
Denys, P., Juan Carlos Castaño Botero, Barton Wachs, et al.. (2022). AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2). Neurourology and Urodynamics. 42(1). 153–167.
3.
Denys, P., Antonella Giannantoni, Christine Thompson, et al.. (2021). Significant reduction of urinary incontinence episodes in patients with neurogenic detrusor overactivity treated with abobotulinumtoxinA (aboBoNT-A): Pooled results of the phase III CONTENT program. European Urology. 79. S32–S33.
4.
Graciès, Jean‐Michel, Robert Jech, Peter Valkovič, et al.. (2020). When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?. Brain Communications. 3(1). fcaa201–fcaa201.
5.
Pons, Laurent, Claire Vilain, Magali Volteau, & Philippe Picaut. (2019). Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®). Journal of the Neurological Sciences. 407. 116516–116516.
6.
Gelu‐Siméon, Moana, et al.. (2018). Submucosal hematoma: a new distinctive sign during emergency upper digestive endoscopy for ammonia ingestion. BMC Gastroenterology. 18(1). 92–92.
7.
Delafont, Bruno, Kevin Carroll, Claire Vilain, & Emmanuel Pham. (2018). Investigation of mixed model repeated measures analyses and non‐linear random coefficient models in the context of long‐term efficacy data. Pharmaceutical Statistics. 17(5). 515–526.
8.
Jimenez‐Moreno, Cecilia, et al.. (2018). Development of a Pediatric Goal-Centered Upper Limb Spasticity Home Exercise Therapy Program for Use in a Phase-III Trial of Abobotulinumtoxina (Dysport®). Physical & Occupational Therapy In Pediatrics. 39(2). 124–135.
9.
Pons, Laurent, Claire Vilain, & Philippe Picaut. (2018). Outcomes of the first-in-human study with a recombinant botulinum toxin type E (rBoNT-E): Safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA (Dysport®). Toxicon. 156. S93–S93.
10.
Isner-Horobeti, Marie-Ève, Jean‐Michel Graciès, Allison Brashear, et al.. (2017). Duration of effect of abobotulinumtoxinA (Dysport®) in adult patients with lower limb spasticity post-stroke or traumatic brain injury. Annals of Physical and Rehabilitation Medicine. 60. e26–e27.
11.
Marqué, P., Jean‐Michel Graciès, Allison Brashear, et al.. (2017). Duration of effect of abobotulinumtoxinA (Dysport®) in adult patients with upper limb spasticity (ULS) post-stroke or traumatic brain injury. Annals of Physical and Rehabilitation Medicine. 60. e24–e25.
12.
O’Dell, Michael W., Allison Brashear, Robert Jech, et al.. (2017). Dose‐Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. PM&R. 10(1). 1–10.
13.
Marciniak, Christina, Peter McAllister, Heather W. Walker, et al.. (2017). Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial. PM&R. 9(12). 1181–1190.
14.
Gül, Fatma, Michael W. O’Dell, Robert Jech, et al.. (2016). Poster 292 Improvement of Spasticity Following AbobotulinumtoxinA (Dysport®) Injections in Shoulder Muscles in Hemiparetic Patients with Upper Limb Spasticity–Sub‐Analysis of a Prospective, Long‐Term, Open‐Label Study with Single and Repeated Injection Cycles. PM&R. 8(9S). S255–S255.
15.
Graciès, Jean‐Michel, Allison Brashear, Christina Marciniak, et al.. (2016). Duration of effect of abobotulinumtoxinA (Dysport) in adult patients with upper limb spasticity (ULS) post stroke or traumatic brain injury. Toxicon. 123. S35–S35.
16.
Graciès, Jean‐Michel, Allison Brashear, Robert Jech, et al.. (2015). Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. The Lancet Neurology. 14(10). 992–1001.
17.
O’Dell, Michael W., Heather W. Walker, Jean‐Michel Gracies, et al.. (2015). Poster 36 AbobotulinumtoxinA (Dysport®) in the Treatment of Adult Patients with Upper Limb Spasticity Due to Traumatic Brain Injury. PM&R. 7(9S).
18.
Boccalon, H., et al.. (1997). Characteristics of chronic venous insufficiency in 895 patients followed in general practice.. PubMed. 16(4). 226–34.
19.
Boccalon, Henri, et al.. (1996). Therapeutic equivalence of two dosage forms of a micronized flavonoid fraction in patients with chronic venous insufficiency. Current Therapeutic Research. 57(10). 757–766.
20.
Zalcman, Gérard, et al.. (1990). [Aortic-pulmonary chemodectoma (non-chromaffin paraganglioma). Apropos of a case which followed an adrenal pheochromocytoma].. PubMed. 7(3). 283–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Benjamin Zakine Breakdown of academic impact, for papers by Serdar Koçer Breakdown of academic impact, for papers by Maria Francesca Micello Breakdown of academic impact, for papers by Angelika Hanschmann Breakdown of academic impact, for papers by Emily Patrick Breakdown of academic impact, for papers by Nicoletta Cinone Breakdown of academic impact, for papers by Heather W. Walker Breakdown of academic impact, for papers by Svetlana Khatkova Breakdown of academic impact, for papers by Susanne Grafe Breakdown of academic impact, for papers by Paul Filipetti